Checking Early Artery Changes and Heart Risk in People with Lupus Nephritis
Studies a blood-based marker of artery changes in adults with lupus nephritis.
Plain-language title generated from the registry record
Registry title: Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Assuit University hospitalsAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT07719322
- Record updated
- 22 July 2026
- Original description
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.Read full original descriptionShow less
Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions.
In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis
Inclusion: Adults aged ≥18 years; Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus; Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis.
Exclusion: Patients on lipid lowering therapy; Established cardiovascular disease (MI, stroke, PAD); Diabetes mellitus; Hypertension; infections; other autoimmune diseases; Malignancy; chronic liver disease; Patient with CKD; Pregnancy; Dyslipidemia; Obesity.